Michael Hartmann

Michael Hartmann

Auto-generated profile, based on publicly available information

Michael Hartmann

Hospital Pharmacy, University Hospital Jena, 07747 Jena, Germany

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Journal of Infection
Verified
Journal Article
Closed access
HAHabibollah Arefian
Habibollah Arefian
SHSteffen Heublein
Steffen Heublein
ASAndré Scherag
André Scherag
FBFrank Martin Brunkhorst
Frank Martin Brunkhorst
MYMustafa Z. Younis
Mustafa Z. Younis
MHMichael Hartmann
Michael Hartmann

11 March 2016 in Deutsches Ärzteblatt international
Verified
Journal Article
Closed access
CFCarolin Fleischmann
Carolin Fleischmann
DTDaniel O. Thomas–Rueddel
Daniel O. Thomas–Rueddel
MHMichael Hartmann
Michael Hartmann
CHChristiane S. Hartog
Christiane S. Hartog
TWTobias Welte
Tobias Welte
KRKonrad Reinhart
Konrad Reinhart
Sepsis, the most severe manifestation of acute infection, can cause multi-organ failure and ends in death in 30?50% of cases (1, 2). According to the National Center for Health Statistics, the annual incidence of sepsis in the USA rose by 7?8% per...

1 January 2000 in Pain
Verified
Journal Article
Closed access
WMWinfried Meissner
Winfried Meissner
USUta Schmidt
Uta Schmidt
MHMichael Hartmann
Michael Hartmann
RKRoland Kath
Roland Kath
KRKonrad Reinhart
Konrad Reinhart
Opioid-related constipation is one of the most frequent side effects of chronic pain treatment. Enteral administration of naloxone blocks opioid action at the intestinal receptor level but has low systemic bioavailability due to marked hepatic first-pass metabolism. The aim of this study was to examine the effects of oral naloxone on opioid-associated constipation in an intraindividually controlled manner. Twenty-two chronic pain patients with oral opioid treatment and constipation were enrolled in this study. Constipation was defined as lack of laxation and/or necessity of laxative therapy in at least 3 out of 6 days. Laxation and laxative use were monitored for the first 6 days without intervention ('control period'). Then, oral naloxone was started and titrated individually between 3x3 to 3x12 mg/day depending on laxation and withdrawal symptoms. After the 4-day titration period, patients were observed for further 6 days ('naloxone period'). The Wilcoxon signed rank test was used to compare number of days with laxation and laxative therapy in the two study periods. Of the 22 patients studied, five patients did not reach the 'naloxone period' due to death, operation, systemic opioid withdrawal symptoms, or therapy-resistant vomiting. In the 6 day 'naloxone' compared to the 'control period', the mean number of days with laxation increased from 2.1 to 3.5 (P<0.01) and the number of days with laxative medication decreased from 6 to 3.8 (P<0.01). The mean naloxone dose in the 'naloxone period' was 17.5 mg/day. The mean pain intensity did not differ between these two periods. Moderate side effects of short duration were observed in four patients following naloxone single dose administrations between 6 and 20 mg, resulting in yawning, sweating, and shivering. Most of the patients reported mild or moderate abdominal propulsions and/or abdominal cramps shortly after naloxone administration. All side effects terminated after 0.5-6 h. This controlled study demonstrates that orally administered naloxone improves symptoms of opioid associated constipation and reduces laxative use. To prevent systemic withdrawal signs, therapy should be started with low doses and patients carefully monitored during titration.

21 October 2002 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
UWUwe Wollina
Uwe Wollina
KLKristin Liebold
Kristin Liebold
WSWolf‐Dieter Schmidt
Wolf‐Dieter Schmidt
MHMichael Hartmann
Michael Hartmann
DFDieter Fassler
Dieter Fassler

1 February 2016 in American Journal of Infection Control
Verified
Journal Article
Closed access
HAHabibollah Arefian
Habibollah Arefian
SHStefan Hagel
Stefan Hagel
SHSteffen Heublein
Steffen Heublein
FRFlorian Rissner
Florian Rissner
ASAndré Scherag
André Scherag
MHMichael Hartmann
Michael Hartmann

5 January 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HAHabibollah Arefian
Habibollah Arefian
MVMonique Vogel
Monique Vogel
AKAnja Kwetkat
Anja Kwetkat
MHMichael Hartmann
Michael Hartmann
This systematic review sought to assess the costs and benefits of interventions preventing hospital-acquired infections and to evaluate methodological and reporting quality. We systematically searched Medline via PubMed and the National Health Service Economic Evaluation Database from 2009 to 2014. We included quasi-experimental and randomized trails published in English or German evaluating the economic impact of interventions preventing the four most frequent hospital-acquired infections (urinary tract infections, surgical wound infections, pneumonia, and primary bloodstream infections). Characteristics and results of the included articles were extracted using a standardized data collection form. Study and reporting quality were evaluated using SIGN and CHEERS checklists. All costs were adjusted to 2013 US$. Savings-to-cost ratios and difference values with interquartile ranges (IQRs) per month were calculated, and the effects of study characteristics on the cost-benefit results were analyzed. Our search returned 2067 articles, of which 27 met the inclusion criteria. The median savings-to-cost ratio across all studies reporting both costs and savings values was US $7.0 (IQR 4.2–30.9), and the median net global saving was US $13,179 (IQR 5,106–65,850) per month. The studies’ reporting quality was low. Only 14 articles reported more than half of CHEERS items appropriately. Similarly, an assessment of methodological quality found that only four studies (14.8%) were considered high quality. Prevention programs for hospital acquired infections have very positive cost-benefit ratios. Improved reporting quality in health economics publications is required.